Dr. Thomas received his medical degree and postgraduate training in Internal Medicine from St. John's Medical College, Bangalore, India, followed by residency in Internal Medicine from the State University of New York Upstate Medical University, Syracuse. He trained in Medical Oncology and Hematology at the Medical Oncology Branch of National Cancer Institute and the National Heart Lung and Blood Institute. He is currently a Lasker Clinical Research Scholar at the National Cancer Institute’s Center for Cancer Research where he established a clinical and translational program committed to accelerating discovery of novel therapies for SCLC patients. Work from the Thomas lab has revealed replication stress as a transformative vulnerability of SCLCs characterized by high neuroendocrine differentiation, targetable by ATR inhibition (Cancer Cell 2021, J Clin Oncol 2018), provided novel insights into the transcriptomic features that render low neuroendocrine SCLC more sensitive to immunotherapy (Nat Commun 2021), and discovered a novel SCLC subset defined by the germline genotype and improved responses to DNA repair targeted drugs (Sci Trans Med 2021).
Anish Thomas, MBBS, MD